GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arcus Biosciences Inc (NYSE:RCUS) » Definitions » Float Percentage Of Total Shares Outstanding

Arcus Biosciences (Arcus Biosciences) Float Percentage Of Total Shares Outstanding : 66.59% (As of Apr. 28, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Arcus Biosciences Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Arcus Biosciences's float shares is 60.57 Mil. Arcus Biosciences's total shares outstanding is 90.95 Mil. Arcus Biosciences's float percentage of total shares outstanding is 66.59%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Arcus Biosciences's Insider Ownership is 5.63%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Arcus Biosciences's Institutional Ownership is 38.44%.


Arcus Biosciences Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Arcus Biosciences's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=60.57/90.95
=66.59%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Arcus Biosciences (Arcus Biosciences) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arcus Biosciences Inc (NYSE:RCUS) » Definitions » Float Percentage Of Total Shares Outstanding
Traded in Other Exchanges
N/A
Address
3928 Point Eden Way, Hayward, CA, USA, 94545
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB680, and Zimberelimab. Arcus conducts clinical trials for different types of cancers such as Prostate, Lung, Colorectal, Pancreatic, and others. The company operates through the single segment being the business of developing and commercializing immunotherapies.
Executives
Goeltz Ii Robert C. officer: Chief Financial Officer 343 OYSTER POINT BLVD, SUITE 100, SOUTH SAN FRANCISCO CA 94080
Juan C. Jaen director, 10 percent owner, officer: President 850 MAUDE AVENUE, MOUNTAIN VIEW CA 94043
Jennifer Jarrett officer: See Remarks C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Alexander Azoy officer: Chief Accounting Officer 30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE CA 91362
Gilead Sciences Inc 10 percent owner 333 LAKESIDE DR, FOSTER CITY CA 94404
Terry J Rosen director, 10 percent owner, officer: Chief Executive Officer C/O TULARK INC, TWO CORP DRIVE S, SAN FRANCISCO CA 94080
Carolyn C. Tang officer: General Counsel 3928 POINT EDEN WAY, HAYWARD CA 94545
Dimitry Sa Nuyten officer: Chief Medical Officer 740 HEINZ AVENUE, C/O ADURO BIOTECH, INC., BERKELEY CA 94710
Linda Slanec Higgins director 3610 LOUIS RD., PALO ALTO CA 94303
Nicole Lambert director 322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
William Grossman officer: Chief Medical Officer C/O BELLICUM PHARMACEUTICALS, INC., 2130 W. HOLCOMBE BLVD., STE. 800, HOUSTON TX 77030
Yasunori Kaneko director, 10 percent owner 509 ROEHAMPTON, HILLS BOROUGH CA 94010
Kathryn E Falberg director C/O AXOVANT SCIENCES, INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018
Michael Quigley director 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Andrew J Perlman director 618 MIRADA AVE, STANFORD CA 94305